Last reviewed · How we verify

Lartruvo — Competitive Intelligence Brief

Lartruvo (OLARATUMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platelet-derived Growth Factor Receptor alpha Antagonist. Area: Oncology.

marketed Platelet-derived Growth Factor Receptor alpha Antagonist Platelet-derived growth factor receptor alpha Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Lartruvo (OLARATUMAB) — Eli Lilly.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lartruvo TARGET OLARATUMAB Eli Lilly marketed Platelet-derived Growth Factor Receptor alpha Antagonist Platelet-derived growth factor receptor alpha 2016-01-01
Ayvakit AVAPRITINIB Blueprint Medicines marketed Kinase Inhibitor [EPC] Platelet-derived growth factor receptor alpha 2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platelet-derived Growth Factor Receptor alpha Antagonist class)

  1. Eli Lilly · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lartruvo — Competitive Intelligence Brief. https://druglandscape.com/ci/olaratumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: